Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2023-0091 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von John J Sheehan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA. Hauptthemen laut MEDLINE: Major Depressive Disorder. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Major depressive disorder (MDD) is a debilitating illness in which depressive symptoms may persist after treatment. Treatment inertia is the continued use of the same pharmacotherapy regimen when treatment goals are not met. This study assessed the frequency of treatment inertia among adult patients with MDD treated in a real-world setting. Patients & methods: This was a retrospective, observational study of patients with MDD identified in the Decision Resources Group Real World Evidence US Data Repository from January 2014 to June 2018. Patients (≥18 years) had an elevated Patient Health Questionnaire-9 (PHQ-9) score (≥5) following 8 weeks of stable baseline antidepressant use with/without mental-health outpatient therapy. Treatment inertia, modification and discontinuation were evaluated over a 16-week follow-up period (timeline based on the APA Practice Guidelines). The primary outcome was the proportion of MDD patients experiencing treatment inertia.
Results
2850 patients (median age, 55 years; 74% female) met the study criteria. Of these patients, 834 (29%) had study-defined treatment inertia, 1534 (54%) received treatment modification and 482 (17%) discontinued treatment. Use of mirtazapine (Odd ratio [OR]: 0.63; 95% confidence interval [CI]: 0.50–0.79), selective serotonin reuptake inhibitors (OR: 0.64; 95% CI: 0.54–0.75) or bupropion (OR: 0.71; 95% CI: 0.60–0.84) in the baseline period was associated with an increased likelihood of treatment modification versus not receiving treatment with these medications. Frequency of treatment inertia may differ among those who do not have a documented PHQ-9 score.
Conclusion
Effective symptom management is critical for optimal outcomes in MDD. Results demonstrate that treatment inertia is common in MDD despite guidelines recommending treatment modification in patients not reaching remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Janssen Scientific Affairs, LLC, Titusville, NJ 08560, USA.
- Health Outcomes Research, Decision Resources Group, Boston, MA 02116, USA.
- Analytics, Decision Resources Group, Boston, MA 02116, USA.
- Department of Psychiatry, University of California San Francisco, San Francisco, CA 94143, USA.
Zitieren
APA
Sheehan, J. J., LaVallee, C., Maughn, K., Balakrishnan, S., Pesa, J. A., Joshi, K., & Nelson, C. (2024). Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0091
Vancouver
Sheehan JJ, LaVallee C, Maughn K, Balakrishnan S, Pesa JA, Joshi K, et al. Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0091
BibTeX
@article{Sheehan2024,
author = {Sheehan, John J and LaVallee, Chris and Maughn, Keshia and Balakrishnan, Santosh and Pesa, Jacqueline A and Joshi, Kruti and Nelson, Craig},
title = {Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2023-0091}
}
EUVIMED